Jongkundang announced on the 8th that it has obtained product approval from the Ministry of Food and Drug Safety for Empamax S tablets (active ingredients empagliflozin, sitagliptin) in 25/100 mg and 10/100 mg dosages.
With the product approval, Jongkundang expects to provide a new treatment option for patients with type 2 diabetes whose blood sugar is not adequately controlled by combination therapy of empagliflozin and sitagliptin, and to improve medication convenience.
Jongkundang applied for product approval of Empamax S tablets to the Ministry of Food and Drug Safety on May 14 last year and plans to launch it in the domestic market in November.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
